《新股表現》嘉和生物-B(06998.HK)暗盤高開50%報36元
根據輝立交易平台顯示,明天掛牌的嘉和生物-B(06998.HK)暗盤高開50%報36元,高低見38.15/34.8元,現造36.3元,較上市價24元,高51%,成交459萬股。
嘉和是一家正在進入商業化階段仍未錄得盈利的生物製藥公司,其專注於腫瘤及自身免疫藥物的研發及商業化,而一直在研發的候選藥物涵蓋全球前三大腫瘤靶標及十款最暢銷藥物中的五款。
是次在港上市共發售近1.2億股,並已引入高瓴資本、淡馬鍚旗下Aranda Investments、泰格醫藥(03347.HK)及雲峰金融(00376.HK)旗下萬通保險及中國平安(02318.HK)等12名基石投資者合共認購5,994萬股;10%公開發售獲1,246.5倍超購,已啟動回撥機制佔比增至50%,認購一手中籤率僅3%;股份以招股範圍(20.3-24元)上限定價,料集資淨額約26.94億元,主要用於為核心產品及其他主要產品研發活動提供資金、撥付研發中其他候選藥物正在進行及計劃中臨床試驗、適應症擴展及註冊案籌備,以及用於為藥物管線擴展提供資金等。上市聯席保薦人分別為高盛、摩通及富瑞。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.